Today is the deadline for public comments on Medicare’s proposed rule for how it will pay for hospital outpatient services and clinician-administered drugs in 2023.
340B stakeholders will be paying close attention to comments on how Medicare Part B should
…
The Commonwealth Fund, a well-respected think tank focused on promoting a high-performance and equitable healthcare system, published a primer on the 340B program last week, highlighting the program’s growth and the controversy its growth has sparked.
“We did the report
…
In a new study published in Health Affairs, researchers find that drug manufacturers are likely to profit from donations they make to patient assistance charities that help patients cover out-of-pocket costs associated with expensive treatments for serious and often rare
…
Eighty percent of all hospitals in Medicare’s outpatient prospective payment system—including 52% of all 340B hospitals—would see their net OPPS payments decline next year if Medicare ends a nearly 30% cut in 340B hospitals’ drug payments that began in 2018,
…
U.S. Public Health Service Rear Adm. Krista Pedley, a top official at the Health Resources and Services Administration (HRSA) and former longtime head of the 340B drug pricing program, has been selected by the American Society of Health-System Pharmacists (ASHP)
…
SPONSORED CONTENT
At AllianceRx Walgreens Pharmacy, each covered entity we meet with describes circumstances unique to its hospital, patients, and pharmacy arrangements. The common element for all is the increasing complexity of 340B programming – often changing by the day. Other themes we often hear about include variable patient volumes, unpredictable cost trends and operational challenges.
These themes magnify when treating patients with complex and rare conditions as diagnosis-to-treatment timelines lengthen and treatment costs typically increase. To effectively serve these patients, specialty medications are a critical component of maximizing 340B program value.
Specialty medications are high-touch, high-cost therapies that treat rare and complex conditions. At AllianceRx Walgreens Pharmacy, we partner with biopharma manufacturers to solve the wide range of challenges often inherent to these therapies. Many of these products must adhere to intricate storage, temperature, and special handling requirements, and can be expensive. In
…
A federal district judge on Wednesday continued the stay in community health centers’ lawsuit against federal health officials over the administrative dispute resolution process for the 340B program after accepting the explanation for a missed deadline to file a report
…
The Biden administration is requesting $27 billion to combat monkeypox and COVID-19 as part of a stopgap spending bill to fund the government past the end of fiscal year 2022, which ends Sept. 30. Senate Republicans are signaling skepticism and
…
A federal district judge in Washington, D.C., yesterday ordered community health centers to answer why she should not dismiss their lawsuit against federal health officials over the administrative dispute resolution process for the 340B program.
Judge Florence Pan of U.S.
…
Congressional Medicare advisers are weighing whether to recommend converting the 6% add-on to Part B drug reimbursement to a fixed fee capped at $175 for drugs that cost $15,000 or more, phased in starting with drugs costing above $700.
Medicare
…*Sign up for news summaries and alerts from 340B Report
